Malignant tumors of vulva

Česká verzia

Authors: Luboš Minář ; J. Kümmel; J. Chovanec
Authors place of work: Gynekologicko-porodnická klinika LF MU a FN Brno
Published in the journal: Prakt Gyn 2009; 13(3): 148-152

Summary

Malignant tumors of vulva constitute 3–4% of gynecological malignancies. They can be successfully treated and if they are recognized at an early stage, are often remediable. Squamous cell cancer of vulva (accounts for approximately 90% of cases) is divided into two basic types according to etiology. Type I is associated with HR-HPV infection and risk factors are similar to those of cervical cancer, for type II play a key role accumulated genetic mutations in the context of higher age and chronic irritation in the field non neoplastic disorders of vulva. Prognosis of disease depends on the particular stage of the disease, is also very important age and performance status of patients, which are factors that limit optimal extent surgical treatment as an essential therapy. Treatment options are derived depending on the stage of disease. Surgical treatment or radiotherapy are highly effective in the early stages. Radiotherapy is a method of choice in advanced stages. Chemotherapy for locally advanced cancer of vulva may be indicated as neoadjuvant therapy in order to create conditions for the subsequent radical surgical performance, by disseminated forms of the disease is used with the intention palliative.

Key words:
vulvar cancer – etiology – therapy

Zdroje

1. Novotvary 2003 ČR, 2006. ÚZIS ČR, NOR ČR.

2. Motlík J, Živný J. Patologie v ženském lékařství. Praha: Grada Publishing 2001.

3. Rob L, Pluta M, Robová H et al. Zhoubné nádory vulvy. Mod Gyn Por 2000; 9(4): 624–633.

4. Apgar BS, Brotzman GL, Spitzer M. Colposcopy, principles and practice: an integrated textbook and atlas. Philadelphia: Saunders 2002.

5. Benedet JL, Bender H, Jones H 3rd et al. FIGO staging classifications and clinical practice guidelines in the management of gynecologic cancers. FIGO committee on Gynecologic Oncology. Int J Gynaecol Obstet 2000; 70(2): 209–262.

6. Raspagliesi F, Hanozet F, Ditto A et al. Clinical and pathological prognostic factors in squamous cell carcinoma of the vulva. Gynecol Oncol 2006; 102(2): 333–337.

7. Rob L. Současné trendy v léčbě gynekologických zhoubných nádorů. Gynekologie po promoci 2006; 6(2): 47–51.

8. Levenback C, Burke TW, Gershenson DM et al. Intraoperative lymphatic mapping for vulvar cancer. Obstet Gynecol 1994; 84(2): 163–167.

9. Cibula D. Chirurgická léčba gynekologických malignit. Mod Gyn Por 2007; 16(3): 533.

10. Gaducci A, Cionini L, Romanini A et al. Old and new perspectives in the management of high‑risk, locally advanced or recurrent, and metastatic vulvar cancer. Crit Rev Oncol Hematol 2006; 60: 227–241.

11. Šlampa P a kol. Radiační onkologie v praxi. Brno: MOÚ 2004.

12. Šlampa P a kol. Radiační onkologie. 2. vyd. Brno: MOÚ 2007.

13. Novotný J, Vítek P, Petruželka L. Klinická a radiační onkologie pro praxi. Praha: Triton 2005.

14. Geisler JP, Manahan KJ, Buller RE. Neoadjuvant chemotherapy in vulvar cancer: Avoiding primary exenteration. Gynecol Oncol 2006; 100(1): 53–57.